milestones news from FierceBiotech
News
Osiris sells stem cell business to NuVasive
Medical device maker NuVasive is buying Osteocel, Osiris' biologics business, for $35 million up front and an additional $50 million in milestone payments. The Osteocel business includes an adult Read more...
Struggling VaxGen sells anthrax vaccine to rival
After spending $175 million in an unsuccessful effort to push a new anthrax vaccine into the clinic, VaxGen has sold the program to Emergent BioSolutions for $2 million. VaxGen also stands to earn Read more...
SPOTLIGHT: Epix wins $7.5M milestone
Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...
ALSO NOTED: Curis earns $3M milestone; Lethal viral outbreak in China; and much more...
> Roxro Pharma announced it has received an Excellence and Innovation Award from the Committee on Scientific Papers of the Society for Ambulatory Anesthesia for the Phase III data of the company's Read more...
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
Sepracor inks $47M IP licensing deal with Arrow
Sepracor has struck a licensing deal with Arrow International Limited for the intellectual property rights related to stable sterile steroid suspension formulations and other applicable nebule Read more...
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
FDA approves Wyeth, Progenics drug
There's a big sigh of relief coming from Wyeth and Progenics today as the FDA approved Relistor, a subcutaneous injection for opioid-induced constipation in patients with advanced illness who are Read more...
Dyax forges $231M development deal for DX-88
Cubist Pharmaceuticals has agreed to pay Dyax $15 million upfront and up to $216.5 million more in potential milestone payments for collaboration rights to Dyax's experimental therapy for the Read more...
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight